Mogrify Ltd extends Series A financing to $46m

The additional commitment of US$10m that results in US$46m raised was made by the new lead investors Astellas Venture Management and Parkwalk Advisors. Ahren Innovation Capital, Trend Investment Group, and Dr. Jonathan Milner, co-founder of Abcam plc, participated in the financing.The company announded it will use the proceeds to advance Mogrify’s pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimisation, and facilitation of new and existing biopharma collaborations.

Cambridge-based Mogrify Ltd has a direct cellular reprogramming platform, which leverages transcriptomic data to identify optimal combinations of transcription factors for the conversionof any cell type into any other cell type. epiMOGRIFY® is a cell identity platform, which leverages epigenetic data to identify optimal combinations of transcription factors or growth factors required to maintain cell identity and epigenetically support the reprogramming of cells in chemically defined media. The company’s pipeline targets degenerative diseases of the eye, ear and pancreas via direct in-vivo restoration of clinically relevant cell types.